Roche

We advance science so that we all have more time with the people we love.
Read our community guidelines:

[Roche @Roche]

#MEDIA – We are pleased that the US FDA has accepted the New Drug Application for our investigational medicine in ER-positive early-stage #BreastCancer in the adjuvant setting https://t.co/XTxzmCLzkM $ROG $RHHBY

[Roche @Roche]

Hi Marah

Thank you for getting in touch with https://t.co/9HEamcLmL1 ensure that the right team takes care of your request, we would invite you to get in touch with our office in your country. You can find a list of all Roche offices at this link: https://t.co/AJXxzupqSU
Or contact us at https://t.co/53pdlSvuJP

Wishing you all the very best.
Ana at Team Roche

[Roche @Roche]

Mass spectrometry is transforming diagnostics, but simply having the tech isn't enough. The real breakthrough comes from seamlessly integrating it into the lab's entire workflow. Hear from Roche’s Benjamin Lilienfield about the value of integration to healthcare labs.

https://t.co/sFIs9136tn

#RocheMassSpec

[Roche @Roche]

#MEDIA - Chronic liver disease causes more than two million deaths worldwide every year, despite 90% of cases being preventable. To help address this, Roche is launching a comprehensive Liver Disease Panel, featuring certified algorithms to improve early detection. https://t.co/No4nRkJ48D

#DigitalHealth #EarlyDetection #CLD

[Roche @Roche]

@gardp_amr Thank you! It was an honour to co-host this vital discussion on global health security at #WHA79

Kat at Team Roche

[Roche @Roche]

Big News from the World Health Assembly! 🌍 Roche and the @MedsPatentPool sign voluntary license agreement to expand global access to innovative antiviral medicine in low-and-middle income countries and strengthen global health resilience against influenza 🏥

For more information, visit: https://t.co/8JuwmJh7Wp

#GlobalHealth #AccesstoMedicines #HealthSecurity #GlobalHealthSecurity #PandemicPreparedness #VoluntaryLicensing #WHA79

[Roche @Roche]

In critical care, every second counts. And now scientists can generate answers – in record time.

Hear about how sequencing by expansion (SBX) technology is evolving genomics: https://t.co/YMmiVmLHYL

(The SBX technology is in development and not commercially available. The content of this material reflects current study results and/or design goals.)

#Genomics #HumanGenetics #RocheSBX #Innovation #NGS

[Roche @Roche]

Alzheimer's changes can start decades before symptoms, a critical window for intervention. Roche is tackling this with blood technologies for earlier detection, helping individuals plan care and slow disease progression. https://t.co/2Qo5JY4GIM

#Innovation #Healthcare #Technology #Alzheimers #Neuroscience

[Roche @Roche]

#MEDIA – We are pleased to share our data from nine approved and investigational medicines at #ASCO26, with the potential to advance the treatment of #breast, #lung, #bladder, #colon cancers and #lymphoma.

https://t.co/CTaZF5MFLv

$ROP $RHHBY

[Roche @Roche]

#MEDIA - New data show the Elecsys pTau217 blood test achieves accuracy comparable to PET for detecting Alzheimer's amyloid pathology, enabling scalable testing from a simple blood draw in routine care settings. https://t.co/4YjnGnVrcy

#Healthcare #Alzheimers #Neuroscience

$ROG $RHHBY

[Roche @Roche]

This #WorldLupusDay, we’re raising awareness of the real-world impact of lupus, and the realities people face everyday.

Around 3.4 million people worldwide are living with #SystemicLupusErythematosus (SLE).

Up to 1 in 3 adults with SLE have #LupusNephritis at diagnosis, and up to 50% may develop it within five years.

Lupus can affect multiple organs, including the kidneys, and it can take 2-6 years to receive an accurate diagnosis - during which time disease flares may lead to irreversible organ damage and reduced quality of life. Click here to learn more about SLE and lupus nephritis!

#LupusAwarenessMonth #LivingWithLupus #SystemicLupusErythematosus #SLE #LupusNephritis

[Roche @Roche]

Hi

Thank you for getting in touch with us. Please submit your complaint via this contact form: https://t.co/WdE8rSBI6U as they will be able to support you best.

Additionally, you can get in touch with our Diabetes Care office in your country to get additional guidance. Here is a link with a list of all our offices around the world: https://t.co/AJXxzupqSU

Wishing you all the very best.
Ana at team Roche

[Roche @Roche]

Dear Saiyed

We are very sorry to hear about this. To help you resolve the issue, please contact our local team at 1800 120 6020 or via email at [email protected]. You can also visit Accu-Chek India Contact Us - https://t.co/iPBtijLfnF . In the meantime, we have forwarded your concern to the relevant team as well.

We hope this issue is resolved soon.

Take care,
Ana at Team Roche

[Roche @Roche]

How could sequencing by expansion (SBX) technology could shape cancer research? Find out more: https://t.co/3Lz9pHUDt2

(The SBX technology is in development and not commercially available. The content of this material reflects current study results and/or design goals.)

#Genomics #HumanGenetics #RocheSBX #Innovation #NGS

[Roche @Roche]

#MEDIA - At #ARVO2026, we’re pleased to share promising data showing progress in preserving vision and managing complex retinal conditions. https://t.co/yQC1GJva21

[Roche @Roche]

¡Felicitaciones a la Cámara de Comercio de Quito por estos 120 años! En Roche compartimos esa visión de trabajo articulado y estamos convencidos de que la productividad y la innovación son motores clave para el bienestar del país. Es un gusto seguir construyendo juntos. 🇪🇨🤝

Ken del Equipo Roche

[Roche @Roche]

We’re proud to announce our continued collaboration with the @wfhemophilia, through their Humanitarian Aid Program, working together to expand access to care for people with #haemophilia in locations where there is little to no access to treatment.

Read more via their website: https://t.co/Sg6jKEivRS

#BleedingDisorders #PublicHealth #WFHCongress2026

[Roche @Roche]

Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc. For more details, click here ➡️ https://t.co/fMbDs05AyR

$ROG $RHHBY #FinancialResults

[Roche @Roche]

#MEDIA - We’re pleased to share detailed, late-breaking results at #AANAM from two positive Phase III studies of our investigational oral, brain-penetrant medicine in relapsing multiple sclerosis. https://t.co/yQC1GJva21

$RHHBY $ROP

[Roche @Roche]

#MEDIA - At #AANAM , we’re pleased to share new positive Phase III data in myelin oligodendrocyte glycoprotein antibody-associated disease (#MOGAD), a disease for which there are no approved treatments. https://t.co/9XpS4N4WXT

$RHHBY $ROP